Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Encompass Pharmaceutical Services Inc.
EIR
•Encompass Pharmaceutical Services Inc.•June 3, 2022

Encompass Pharmaceutical Services Inc. – FDA EIR, Jun 3, 2022

Record Details

The FDA conducted a comprehensive inspection of Encompass Pharmaceutical Services Inc. in Peachtree Corners, GA, from May 23 to June 3, 2022. Operating as a chemical/physical contract testing laboratory, the firm is subject to drug manufacturing regulations under the Food Drug and Cosmetic Act.The inspection revealed several significant issues, detailed in a Form FDA 483 issued to the owner, Thomas Rowe. Key violations included a systemic failure to initiate deviation and Out-of-Specification (OOS) investigations, particularly regarding stability chamber monitoring deficiencies such as missing temperature/humidity records and prolonged OOS conditions. The firm also lacked adequate stability data to support drug product expiration dates, largely due to non-functional continuous monitoring systems, insufficient raw chart recorder data, and conflicts between documented logbook entries and raw data. Furthermore, controls over computer systems were inadequate, with data integrity Standard Operating Procedures (SOPs) failing to properly address audit trail reviews, a recurring issue from a 2019 Health Canada audit. Lastly, routine equipment calibration was found deficient, with missing or inadequate SOPs for stability chamber operation and sensor calibration.Management, through Mr. Rowe, acknowledged the observations and committed to submitting a written response to the FDA 483 within 15 business days, including efforts to retrieve missing data. The firm was reminded of its ongoing responsibility to comply with regulatory requirements, with potential consequences ranging from warning letters to legal penalties for non-compliance.

Company
Encompass Pharmaceutical Services Inc.
Inspection date
June 3, 2022
Product type
drugs
Office
Atlanta District Office
Person
  • Susan O. Oladeji
View Company Profile

ID · 6a9d512e-0f1c-4b24-ae85-7b9e50cc9c74

Violation Codes4
21 CFR 211.68(a)21 CFR 211.68(b)21 CFR 211.137(a)21 CFR 211.192

Full citation text and observation details available on the Dashboard.

Other documents for Encompass Pharmaceutical Services Inc.
  • 483 - 2022-06-03June 3, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Encompass Pharmaceutical Services Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.